Oragenics (OGEN) Files for 2.4M Share and Warrant Offering

Oragenics (NYSE: OGEN) has filed the following:

This is a reasonable best efforts public offering of up to 2,403,846 shares of our common stock at an assumed public offering price of $2.08 per share, the last reported sale price of our common stock as reported on NYSE American, or the “NYSE American,” on August 12, 2024. The actual public offering price per share of common stock will be determined between us and the Placement Agent at the time of pricing and may be at a discount to this assumed offering price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final offering price.

We are also offering pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,403,846 shares of Common Stock to those purchasers whose purchase of shares of Common Stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the consummation of this offering, in lieu of shares of Common Stock. Each Pre-Funded Warrant is exercisable for one share of Common Stock and has an exercise price of $0.001 per share. The assumed offering price per Pre-Funded Warrant is $2.08 less $0.001. Each Pre-Funded Warrant will be exercisable immediately upon issuance and will expire when exercised in full. This offering also relates to the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants sold in this offering.

You May Also Be Interested In

• BofA Securities Upgrades Saia Inc. (SAIA) to Buy
• Vertical Aerospace delays Valo certification to 2029, gets expanded CAA permit
• Faraday Future cancels 50M warrants, outlines robotics strategy